Turoctocog Alfa Pegol

Summary

Turoctocog Alfa Pegol (CHEMBL5315071) is an approved protein; indicated across 1 condition including hemophilia a.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Indications: 1 condition
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315071
Name	Turoctocog Alfa Pegol
Type	Protein
Max phase	4

Also known as: Esperoct, Turoctocog alfa pegol, TUROCTOCOG ALFA PEGOL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hemophilia A	4	MONDO:0010602	MONDO:0010602

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE3	6
Not specified	4
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01480180	PHASE3	COMPLETED	Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
NCT01489111	PHASE3	COMPLETED	Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
NCT01731600	PHASE3	COMPLETED	A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
NCT02137850	PHASE3	COMPLETED	Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
NCT03528551	PHASE3	COMPLETED	A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A
NCT05082116	PHASE3	COMPLETED	Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
NCT01205724	PHASE1	COMPLETED	Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
NCT02920398	PHASE1	COMPLETED	A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A
NCT02994407	PHASE1	COMPLETED	Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A
NCT04574076	Not specified	ENROLLING_BY_INVITATION	A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
NCT04682145	Not specified	ENROLLING_BY_INVITATION	Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
NCT05621746	Not specified	RECRUITING	An Observational Research Study of the Health of Joints in People With Haemophilia Taking the Medicine Esperoct
NCT04334057	Not specified	COMPLETED	Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).